drugset / Trial / NCT00019383
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
Treatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Giving the vaccine with interleukin-2 or sargramostim may help kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of peptide vaccine with or without adjuvant interleukin-2 or sargramostim in treating patients who have recurrent or refractory metastatic melanoma.
Timeline
- Start
- 1998-01
- Primary completion
- —
- Completion
- 2003-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Intravenous |
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |
| Subject | tyrosinase peptide | Peptide | — | Subcutaneous |
| Subject | tyrosinase-related protein-1 | Vaccine | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | — |